At Hackensack University Medical Center, research to improve the understanding and treatment of cancer is happening at a rapid pace—in our basic science laboratories, in our clinics through clinical trials, and through translational research efforts that link the two.
A Dedicated Research Team
In addition to the physicians who care for you, our clinical research team includes more than 100 staff members dedicated just to the research program, including research nurses, data coordinators, research finance professionals, and other healthcare professionals. We recognize and appreciate the value of each and every patient who participates in our research studies, and we work together to ensure that your experience during your enrollment in a clinical trial is as positive and rewarding as it can be.
Robert Korngold, PhD
Ernest Richards, PhD, FACN
Director of Research
Changing the Future of Cancer through Collaboration
Through our partnership with the National Cancer Institute’s Immunology branch, Georgetown University’s Lombardi Comprehensive Cancer Center, the Parker Institute for Cancer Immunotherapy, and Memorial Sloan Kettering, we are propelling advances in novel anticancer treatments, including immunotherapy and cellular therapies. Progress in the development, assessment, and FDA approval of these treatments is happening at an accelerating pace, and you may be able to benefit from these innovative therapies right here at John Theurer Cancer Center.
Embracing Precision Medicine
We are using precision medicine to tailor the optimal type and sequence of treatment for each of our patients. Our clinical experience and resources will allow us to implement precision medicine in ways that benefit patients today and in the future.
A Commitment to Translational Research
Translational research (“bench-to-bedside”) efforts promote the extension of new developments from basic science research laboratories to the clinic, where they may help patients. In our David Joseph Jurist Center for Research and through our affiliations with Georgetown’s Lombardi Comprehensive Cancer Center and the Stevens Institute of Technology in New Jersey, we are dedicated to translational research. Our scientists are studying epigenetic factors that affect various cancers, novel approaches to improve outcomes following hematopoietic stem cell transplantation, and how immunotherapy can be influenced by immune cells and the microbiome. We are also opening a comprehensive translational science center and a new medical school in collaboration with Seton Hall University, in Nutley, New Jersey, at the former location of Hoffmann-La Roche.OUR TRANSLATIONAL MEDICINE PROGRAM
Implementing Value-Based Care with Big Data
COTA (Cancer Outcomes Tracking and Analysis) is an initiative using “big data” to identify the best way to treat patients with similar disease characteristics. By precisely classifying our patients at the time of diagnosis and by implementing real-time analytical methods to interpret the data we collect, we are empowering cancer professionals with high-quality research data, creating alternative healthcare payment models, creating national benchmarks for patient outcomes, accelerating drug discovery and approval, and helping patients make informed decisions about their own care. COTA has the power to improve clinical outcomes for each patient. By optimizing treatment decision-making, we can also reduce cancer care costs along the way.
You may also be interested in
A child with a primary immune deficiency has an immune system that does not work at all, or does not work well, usually due to a hereditary or genetic defect. When that happens, the child will have a reduced ability to resist or get rid of an infectious disease.
Translational research by definition brings knowledge from bench to bedside to offer as early as possible advanced options in difficult to treat cancers. This includes a strong dedication from John Theurer Cancer Center to customize treatment through precision medicine.
The Genetics Service, a leader in clinical genetics in the metropolitan area for over 30 years, offers genetic services and testing for both children and adults. The goal is to provide patients with the important information they need through risk assessment evaluations, testing, management, and supportive counseling.
The Lymphoma Division at John Theurer Cancer Center involves a comprehensive team of professionals who are dedicated to treating patients with lymphoma (cancer of the immune system), which includes Hodgkin’s disease, Non-Hodgkin’s lymphoma and Chronic Lymphocytic Leukemia.